Article
Medicine, General & Internal
Kristian Reich, Kim A. Papp, Andrew Blauvelt, Richard G. Langley, April Armstrong, Richard B. Warren, Kenneth B. Gordon, Joseph F. Merola, Yukari Okubo, Cynthia Madden, Maggie Wang, Christopher Cioffi, Veerle Vanvoorden, Mark Lebwohl
Summary: Bimekizumab was more effective than ustekinumab and placebo in the treatment of moderate to severe plaque psoriasis, with a safety profile consistent with previous studies.
Article
Pharmacology & Pharmacy
Wangda Zhou, Chuanpu Hu, Yaowei Zhu, Bruce Randazzo, Michael Song, Amarnath Sharma, Zhenhua Xu, Honghui Zhou
Summary: A population pharmacokinetic model and a joint longitudinal exposure-response model were developed to characterize the PK and exposure-response relationship of ustekinumab in pediatric patients with psoriasis. The models predicted the PK of ustekinumab and the clinical response in pediatric patients with psoriasis, showing efficacy and safety in this population.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Medicine, General & Internal
Laida Elberdin, Rosa M. Fernandez-Torres, Maria Mateos, Maria Outeda, Eva Blanco, Maria I. Gomez-Besteiro, Isabel Martin-Herranz, Eduardo Fonseca
Summary: This study found a positive correlation between ustekinumab concentration and clinical response in psoriatic patients, suggesting ustekinumab concentration could be used to predict treatment efficacy. The presence of anti-ustekinumab antibodies may serve as a potential cause for treatment failure.
FRONTIERS IN MEDICINE
(2022)
Article
Medicine, General & Internal
Kenneth B. Gordon, Peter Foley, James G. Krueger, Andreas Pinter, Kristian Reich, Ronald Vender, Veerle Vanvoorden, Cynthia Madden, Katy White, Christopher Cioffi, Andrew Blauvelt
Summary: The study demonstrated that Bimekizumab showed high levels of response in patients with moderate to severe plaque psoriasis, with durable effects over 56 weeks under both maintenance dosing schedules (every 4 weeks and every 8 weeks). Additionally, Bimekizumab was well tolerated with no unexpected safety issues, further supporting its therapeutic value for this patient population.
Review
Pediatrics
Hannah A. Blair
Summary: Subcutaneous secukinumab is an effective treatment option for children and adolescents with moderate to severe plaque psoriasis, providing fast and durable skin clearance, continuous improvement in health-related quality of life, and long-term maintained benefits.
Review
Dermatology
Yara E. Aljefri, Abdullah A. Ghaddaf, Tala A. Alkhunani, Taif A. Alkhamisi, Rana A. Alahmadi, Awadh M. Alamri, Ali A. Alraddadi
Summary: This study evaluated the efficacy and safety of apremilast monotherapy for moderate-to-severe plaque psoriasis. The results indicated that apremilast was more effective than placebo in achieving PASI-75, with higher rates of adverse events observed in the 30 mg BID group.
DERMATOLOGIC THERAPY
(2022)
Article
Pharmacology & Pharmacy
Yuqian Wang, Sheng Li, Juan Bai, Xiaoxuan Cai, Shunli Tang, Peiyi Lin, Qingmiao Sun, Jianjun Qiao, Hong Fang
Summary: This study evaluated the efficacy and safety of bimekizumab in treating patients with psoriasis and determined the optimal maintenance dosing schedules. The results showed that bimekizumab had better efficacy than placebo or active comparators in treating psoriasis. After 16 weeks of initial maintenance treatment, both bimekizumab maintenance dosing schedules (320 mg every 4 and 8 weeks) had similar efficacy.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE
(2023)
Article
Dermatology
Ricardo Ruiz-Villaverde, Fiorella Vasquez Chinchay, Lourdes Rodriguez-Fernandez-Freire, Jose C. Armario-Hita, Amalia Perez-Gil, Manuel Galan-Gutierrez
Summary: This retrospective observational study examined the outcomes of psoriatic patients with moderate-to-severe psoriasis who switched from ustekinumab to guselkumab treatment. The results showed that guselkumab administered every 12 weeks without induction achieved good effectiveness and safety profiles in clinical practice.
DERMATOLOGIC THERAPY
(2022)
Article
Dermatology
April W. Armstrong, Ahmed M. Soliman, Keith A. Betts, Yan Wang, Yawen Gao, Vassilis Stakias, Luis Puig
Summary: Through network meta-analysis, risankizumab was found to have the most favorable long-term benefit-risk profile for the treatment of moderate-to-severe plaque psoriasis, while ixekizumab and bimekizumab showed good efficacy but lower rankings for safety outcomes.
DERMATOLOGY AND THERAPY
(2022)
Article
Dermatology
April W. Armstrong, Ahmed M. Soliman, Keith A. Betts, Yan Wang, Yawen Gao, Luis Puig, Matthias Augustin
Summary: This study evaluated the efficacy of biologic and oral treatments for moderate-to-severe psoriasis, finding that ixekizumab, risankizumab, and brodalumab had the highest short-term efficacy, while risankizumab demonstrated the highest long-term efficacy.
DERMATOLOGY AND THERAPY
(2021)
Review
Oncology
Yuxiong Jiang, Youdong Chen, Qian Yu, Yuling Shi
Summary: Psoriasis is a systemic immune-mediated disease associated with increased risk of multiple comorbidities. With the introduction of biological agents, the efficacy and safety of psoriasis treatments have greatly improved. Different classes of drugs, including tumor necrosis factor-alpha inhibitors, interleukin-17 inhibitors, and small-molecule inhibitors, have been approved for the treatment of moderate-to-severe psoriasis. These drugs not only target psoriasis but also have significant effects on its comorbidities. Understanding the characteristics of these drugs can provide personalized care for patients with distinct comorbidities.
Article
Dermatology
Hidehisa Saeki, Kanako Ishii, Avani Joshi, Arielle G. Bensimon, Hongbo Yang, Isao Kawaguchi
Summary: This study evaluated the cost-effectiveness of risankizumab compared to other biologic treatments for moderate-to-severe psoriasis in Japan. The results showed that risankizumab was associated with higher quality-adjusted life years (QALYs) and lower costs, making it a cost-effective option for treating psoriasis in Japan.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2022)
Article
Immunology
Chen Yu, Furen Zhang, Yangfeng Ding, Yumei Li, Yi Zhao, Jun Gu, Shuping Guo, Weili Pan, Hongzhong Jin, Qing Sun, Xiaojing Kang, Qinping Yang, Xian Jiang, Zhiqiang Song, Qianjin Lu, Xiaowen Pang, Yehong Kuang, Danqi Deng, Yuzhen Li, Chunlei Zhang, Juan Tao, Liangzhi Xie, Yan Wang, Jieying Wang, Gang Wang
Summary: This study compares the efficacy, safety, and immunogenicity of SCT630 and adalimumab in Chinese patients with moderate to severe plaque psoriasis. The results demonstrate the equivalence of SCT630 and adalimumab in terms of efficacy, safety, and immunogenicity.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Medicine, General & Internal
Ran Pan, Xiaolun Wang, Min Shu, Jaydeep Das, Manik Kalra, Zhidong Wang
Summary: The efficacy of SEC in the treatment of patients with moderate-to-severe plaque psoriasis is well demonstrated through NMA.
CHINESE MEDICAL JOURNAL
(2022)
Article
Dermatology
Jensen Yeung, Marc Bourcier, Melinda J. Gooderham, Parbeer Grewal, Chih-Ho Hong, Perla Lansang, Charles Lynde, Catherine Maari, Vimal H. Prajapati, Irina Turchin, Ron Vender
Summary: A group of Canadian dermatologists convened to develop a consensus statement for treating moderate-to-severe plaque psoriasis using biologics. They proposed a multidimensional approach to defining treatment targets and a criterion-based system for determining treatment success.
DERMATOLOGIC THERAPY
(2022)